Characterizing the role of endothelin-1 in the progression of cardiac hypertrophy in aryl hydrocarbon receptor (AhR) null mice
- 15 April 2006
- journal article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 212 (2) , 127-135
- https://doi.org/10.1016/j.taap.2005.07.005
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Ethnic Differences in the Vasoconstrictor Activity of Endogenous Endothelin-1 in Hypertensive PatientsCirculation, 2004
- Endothelin ETA receptor antagonism does not attenuate angiotensin II‐induced cardiac hypertrophy in vivo in ratsClinical and Experimental Pharmacology and Physiology, 2003
- Predictors of Target Organ Damage in Hypertensive Blacks and WhitesHypertension, 2001
- The PAS Superfamily: Sensors of Environmental and Developmental SignalsAnnual Review of Pharmacology and Toxicology, 2000
- Chronic ET A Receptor Blockade Attenuates Cardiac Hypertrophy Independently of Blood Pressure Effects in Renovascular Hypertensive RatsHypertension, 1999
- Myocardial osteopontin expression is associated with left ventricular hypertrophy.Circulation, 1997
- Lesions of Aryl-hydrocarbon Receptor–deficient MiceVeterinary Pathology, 1997
- Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction.Journal of Clinical Investigation, 1996
- Racial Differences in Plasma Endothelin-1 Concentrations in Individuals With Essential HypertensionHypertension, 1996
- Molecular and cellular biology of osteopontin: Potential role in cardiovascular diseaseTrends in Cardiovascular Medicine, 1995